Previous close | 7.60 |
Open | 7.60 |
Bid | 4.80 |
Ask | 6.80 |
Strike | 82.50 |
Expiry date | 2025-01-17 |
Day's range | 7.60 - 7.60 |
Contract range | N/A |
Volume | |
Open interest | 14 |
MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announces a new strategic collaboration with BioNTech SE (Nasdaq: BNTX, "BioNTech"), a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, under which BioNTech will receive an exclusive option to an exclusive global license to apply MediLink's TMALIN® antibody-drug conjugate (ADC) platform, for several novel targets chosen by BioNTech.
MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at the American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, Illinois, from May 31 to June 4, 2024. Moreover, in support of the Company’s ongoing CAR-T cell and individualized mRNA programs, BioNTech will also present epidemiological and real-world data from two observational studi
Q1 2024 Autolus Therapeutics PLC Earnings Call